Immune Design Corp. (NASDAQ:IMDZ)’s share price was down 1.9% during mid-day trading on Friday . The stock traded as low as $7.00 and last traded at $7.24, with a volume of 82,898 shares trading hands. The stock had previously closed at $7.38.

IMDZ has been the topic of several research reports. Wells Fargo & Co. reissued a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Leerink Swann reissued a “buy” rating on shares of Immune Design Corp. in a research note on Friday, June 10th. Zacks Investment Research lowered shares of Immune Design Corp. from a “buy” rating to a “hold” rating in a research note on Friday, May 13th. Cowen and Company reissued a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Finally, Jefferies Group reissued a “buy” rating and set a $20.00 price objective on shares of Immune Design Corp. in a research note on Wednesday, May 11th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Immune Design Corp. presently has an average rating of “Buy” and a consensus target price of $24.00.

The company has a 50 day moving average of $8.99 and a 200-day moving average of $11.57. The firm’s market cap is $144.30 million.

Immune Design Corp. (NASDAQ:IMDZ) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.61) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.01. On average, equities research analysts expect that Immune Design Corp. will post ($2.70) EPS for the current fiscal year.

An institutional investor recently raised its position in Immune Design Corp. stock. Jennison Associates LLC boosted its stake in Immune Design Corp. (NASDAQ:IMDZ) by 0.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 203,452 shares of the company’s stock after buying an additional 769 shares during the period. Jennison Associates LLC owned 1.01% of Immune Design Corp. worth $4,085,000 as of its most recent filing with the SEC.

Immune Design Corp. is a clinical stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its two discovery platforms, ZVex and GLAAS, which it believes have the potential to treat a broad patient population either as individual therapies or in combination with other immuno-oncology mechanisms of action.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.